Skip to main content

Animations

MJFF Publications

3221 - 3230 of 6568 Results
Title
Year
  • Year
  • 2024
  • 2024
  • 2014
  • 2017
  • 2018
  • 2014
  • 2020
  • 2013
  • 2018
  • 2019
  • Summary Details
    OPEN
    Title: Data‐driven disease progression model of Parkinson's disease and effect of sex and genetic variants
    Journal Name: CPT: Pharmacometrics & Systems Pharmacology
    Publisher: Wiley
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1002/psp4.13112
    Citation Count: 11
  • Summary Details
    OPEN
    Title: Clinical prediction of GBA carrier status in Parkinson’s disease
    Journal Name: Clinical Parkinsonism & Related Disorders
    Publisher: Elsevier BV
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.1016/j.prdoa.2024.100251
    Citation Count: 1
  • Summary Details
    OPEN
    Title: Differential role of CSF alpha-synuclein species, tau, and Aβ42 in Parkinson's Disease
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2014.00053
    Citation Count: 171
  • Summary Details
    OPEN
    Title: Distinct Role of Striatal Functional Connectivity and Dopaminergic Loss in Parkinson’s Symptoms
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2017.00151
    Citation Count: 16
  • Summary Details
    OPEN
    Title: The Luxembourg Parkinson’s Study: A Comprehensive Approach for Stratification and Early Diagnosis
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2018.00326
    Citation Count: 98
  • Summary Details
    OPEN
    Title: Elevated levels of cerebrospinal fluid α-synuclein oligomers in healthy asymptomatic LRRK2 mutation carriers
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2014.00248
    Citation Count: 77
  • Summary Details
    OPEN
    Title: Phenotype-Agnostic Molecular Subtyping of Neurodegenerative Disorders: The Cincinnati Cohort Biomarker Program (CCBP)
    Journal Name: Frontiers in Aging Neuroscience
    Publisher: Frontiers Media SA
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.3389/fnagi.2020.553635
    Citation Count: 36
  • Summary Details
    OPEN
    Title: A strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's Research
    Journal Name: Disease Models & Mechanisms
    Publisher: The Company of Biologists
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by
    DOI - Digital Object Identifier: 10.1242/dmm.011940
    Citation Count: 40
  • Summary Details
    OPEN
    Title: Feasibility and Safety of Multicenter Tissue and Biofluid Sampling for α-Synuclein in Parkinson’s Disease: The Systemic Synuclein Sampling Study (S4)
    Journal Name: Journal of Parkinson’s Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-181434
    Citation Count: 24
  • Summary Details
    OPEN
    Title: Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures
    Journal Name: Journal of Parkinson's Disease
    Publisher: SAGE Publications
    Publication Date:
    Open Access(OA) Status: OPEN
    License: cc-by-nc
    DOI - Digital Object Identifier: 10.3233/jpd-181518
    Citation Count: 25
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.